Gencure, a subsidiary of BioBridge Global, offers a variety of ways for you to stay connected with us. You can read our latest press releases or the Annual Reports. Visit the Events Page to find out what’s coming up. You can watch a video clip from a newscast, view past events in the Photo Gallery or read industry news. For the social media enthusiast, the BioBridge family is known as “Connect for Life,” and can be found on FacebookTwitterLinkedIn and YouTube. Also, visit our blog here.

Media is welcome to contact the Corporate Communications Department for more information. We offer:

Interviews with experts in their respective medical fields
  • Interviews with Life Links - community members touched by the services of BioBridge Global
  • Informative tours of the facility

Please contact:
Corporate Communications
Phone: (210) 731-5519
Mobile: (210) 296-9026

Recent News Articles

May 12, 2016

When Erin Nichols was asked to compete for the title of the Leukemia and Lymphoma Society Woman of the Year, she couldn’t say anything but “yes.”

New executive to lead regenerative medicine subsidiary of BioBridge Global
April 14, 2016

Becky Cap, a 20-year veteran of the life sciences industry, has been named chief operating officer of San Antonio-based GenCure.

Cap has worked with GenCure and its parent organization, BioBridge Global, on a part-time basis for the past year. She also served as a volunteer in support of the organization’s efforts as a presenting sponsor of the 2014 World Stem Cell Summit in San Antonio.

“Becky is excited about the team she’s come to know at GenCure and the opportunity to work with them to build on the foundation that’s been put into place, with the goal of moving the organization into a new phase of growth,” said Linda Myers, chief executive officer of BioBridge Global.

A behind the scenes look at your donation for life
April 13, 2016

Guillermo Robles knew he could make a difference when he came to the GenCure tissue center as a tissue recovery team lead.

He had the training. He had the experience. He had the ability to communicate the technical requirements of the job. He jumped in and went right to work, sharing those skills with members of the team.

But until recently, he hadn’t fully realized the impact he had made.

He was at a tissue recovery, handling paperwork and bagging. Two of the techs were doing the actual collection, explaining their procedures to a new member of the team.

“I was at the back table, just watching,” Robles said. “I was surprised, because every time they said something, it was like I was hearing myself.

“That was a pretty nice feeling. My two technicians were teaching what I had taught them three or four months ago. That made me realize I was doing something good around here.”

February 24, 2016

The GenCure tissue donation program is following longstanding procedures set up to screen for mosquito-borne viruses, including Zika.

In the case of postmortem tissue donation, donors diagnosed with a Zika virus infection within the last six months will be ineligible.

Donors of umbilical cord blood and placentas will be asked if they have been diagnosed with a Zika virus infection during pregnancy, or lived in or traveled to a region of Zika transmission during pregnancy. They also will be asked if they had sex during pregnancy with a man diagnosed with a Zika virus infection, or who traveled to a Zika virus transmission area, or lived in one of those areas.

January 22, 2016

The organization that works in partnership with the GenCure Marrow Donor Program has launched a subsidiary to focus on cellular therapy.

The National Marrow Donor Program/Be The Match announced in a news release that it has formed Be The Match BioTherapies, which will focus on forming partnerships with organizations working on developing new cellular therapy treatments.

In the last 25 years, NMDP/Be The Match has facilitated 74,000 marrow and cord blood transplants, as part of therapies for blood and related disorders. Be The Match BioTherapies will use that experience to work with organizations developing and providing new cellular therapies.